title: Addition of anti-neu antibody to local irradiation can improve tumor-bearing BALB/c mouse survival through immune-mediated mechanisms.
abstract: This study investigated the therapeutic effects of combined local irradiation and anti-HER2/neu antibody in a mixed tumor mouse model comprised of a nonmetastatic neu-positive tumor and a metastatic neu-negative tumor. While local irradiation alone could control the primary tumor in a dose-dependent manner, it did not improve mouse survival. Combined treatment comprised of local irradiation and anti-neu antibody of tumor-bearing BALB/c mice significantly improved mouse survival (P < 0.5), even though the tumor growth was similar to that of the irradiated-alone group. The combined treatment significantly reduced metastatic tumor masses in the lung and increased immune cell infiltration in primary tumor tissues. However, immune deficient nude mice with tumors did not exhibit prolonged survival in response to the combined treatment. Collectively, these results show that combined local irradiation and anti-neu antibody can elicit an immune-mediated abscopal effect to extend survival. Although the mechanism for abscopal effects induced by the combined treatment of radiation and anti-HER2/neu antibody was not elucidated, to our knowledge this is the first published study to describe the abscopal effect induced by the combination of local irradiation and the anti-HER2/neu antibody.
authors.affiliation: a Department of Radiation Oncology, Kosin University College of Medicine, Busan, 602-702, Republic of Korea.
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Ma
authors.forename: Hyunkeun
authors.initials: H
authors.lastname: Song
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Park
authors.forename: Jae-Hyeog
authors.initials: JH
authors.lastname: Choi
authors.forename: Jin-Ho
authors.initials: JH
authors.lastname: Kim
authors.forename: Ki Hyang
authors.initials: KH
authors.lastname: Kim
authors.forename: SungJae
authors.initials: S
authors.lastname: Park
authors.forename: Dong Hyen
authors.initials: DH
authors.lastname: Park
authors.forename: Mi Seon
authors.initials: MS
authors.lastname: Kang
authors.forename: Minjung
authors.initials: M
authors.lastname: Kwak
authors.forename: Yang-Xin
authors.initials: YX
authors.lastname: Fu
authors.forename: Inhak
authors.initials: I
authors.lastname: Choi
authors.forename: Heunglae
authors.initials: H
authors.lastname: Cho
authors.forename: SaeGwang
authors.initials: S
authors.lastname: Park
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human